NeuroMetrix Engages IRG for Investor Relations
WALTHAM, Mass.--(BUSINESS WIRE)--May. 24, 2012--
NeuroMetrix, Inc. (Nasdaq: NURO),
www.neurometrix.com,
a medical device company focused on the diagnosis and treatment of the
neurological complications of diabetes, reported today that it has
engaged
IRG, LLC (IRG), a prominent, full service corporate
communications firm, to serve as its investor relations agency.
IRG will implement a campaign targeting portfolio managers, analysts,
and the retail community with the goal of increasing investor awareness
of NeuroMetrix and its role in the fast-growing diabetes sector.
NeuroMetrix is focused on diabetes-related nerve disease (diabetic
peripheral neuropathy or DPN), which is one of the most common
complications of diabetes. DPN affects over 50% of people with diabetes
and can lead to foot ulcers and amputation. The company currently
markets NC-stat® DPNCheck™, a fast, accurate and
quantitative point-of-care test for systemic neuropathies including DPN.
It recently filed with the Food and Drug Administration a 510(k)
premarket notification for the next product in its development pipeline,
the SENSUS™ pain management device, which is designed to help
patients manage chronic pain such as painful diabetic neuropathy.
“There are significant unmet needs in the diagnosis and treatment of
diabetic peripheral neuropathy,” said Shai N. Gozani, M.D., Ph.D.,
President and CEO of NeuroMetrix. “We are making solid progress in
developing medical devices that address the needs of physicians and
patients in this area. IRG has the experience to complement our efforts
by helping us ensure that the investment community is aware of our
activities. We look forward to working closely with IRG.”
IRG, LLC, founded in 1996 as The Investor Relations Group, is a
full-service corporate communications firm. The company provides an
array of services that include targeted introductions to the investment
community as well as the media-at-large through the best of traditional
and new media outlets. IRG’s services also include the creation of
broadcast-ready corporate videos, podcasts, and social media content.
IRG is a wholly owned subsidiary of Direct Markets, Inc. For further
information, please visit the company’s website at www.IRGnews.com.
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices, associated consumables, and
support software for the treatment and management of diabetes and its
complications. The company is focused on nerve related complications of
diabetes, called diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling pain, and increase
the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and other clinicians, in
retail health settings such as pharmacies, and by managed care
organizations to optimize patient care and reduce healthcare costs. The
company markets the NC-stat® DPNCheck™ device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. The company is in late stage
development of SENSUS™, a pain management device that will be
used to treat painful diabetic neuropathy, a form of chronic intractable
pain. Currently, painful diabetic neuropathy is treated
pharmacologically, which is a $2 billion annual market. The company has
additional therapeutic products in its pipeline. For more information,
please visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief
Financial Officer
neurometrix.ir@neurometrix.com
or
IRG,
LLC
Investor Relations:
Adam Holdsworth, 212-825-3210
aholdsworth@investorrelationsgroup.com
